Abstract

Pseudomonas aeruginosa, a notorious opportunistic pathogen, is a leading cause of hospital-acquired infections. The newest generation of β-lactam antibiotics, the carbapenems, are often used to treat multi-drug resistant (MDR) P. aeruginosa infections. Treatment of P. aeruginosa has become increasingly difficult due to its remarkable ability to resist antibiotics through various intrinsic and acquired mechanisms. Physicians rely on a limited group of antibiotics to treat these infections, but many P. aeruginosa isolates are evolving to become resistant to all available antibiotics, including carbapenems. The multifaceted mechanisms underlying P. aeruginosa antibiotic resistance include β -lactamases, efflux pumps, altered membrane porins, and antibiotic binding site mutations of the penicillin binding proteins. There is an urgent need for continued research to better understand the resistance mechanisms used by P. aeruginosa, in order to develop novel therapeutic strategies. The purpose of this project was to investigate the effect of β-lactam antibiotics used in combination with the known efflux pump inhibitor mefloquine, on the growth of MDR P. aeruginosa. The effect of the combination of mefloquine andβ-lactams was investigated in vitro using the checkerboard method. In vitro assays showed that mefloquine when combined with certain β-lactam antibiotics produced no significant additional inhibition than the β-lactams antibiotics alone on MDR P. aeruginosa. Mefloquine, in combination with various β-lactams, did not restore clinically relevant sensitivity, even in those isolates where resistance is thought to be mediated by efflux pumps.

Degree

MS

College and Department

Life Sciences; Microbiology and Molecular Biology

Rights

https://lib.byu.edu/about/copyright/

Date Submitted

2024-08-09

Document Type

Thesis

Handle

http://hdl.lib.byu.edu/1877/etd13382

Keywords

Pseudomonas aeruginosa, multi-drug resistant, efflux pump, mefloquine, β-lactam

Language

english

Included in

Life Sciences Commons

Share

COinS